Update of combined therapies with docetaxel for hormone-independent prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 264-267, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-319230
ABSTRACT
Hormone-independent prostate cancer (HIPC) is the end stage of prostate cancer, with a short median survival of 9-18 months for the patients. Two large phase III studies have demonstrated a survival advantage of docetaxel chemotherapy in HIPC patients. New combined protocols have been developed with promising results. These protocols propose a combination with docetaxel, chemotherapy, antiangiogenic agents, vaccine and biological drugs. This review focuses the progress achieved the combined therapies for HIPC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prostatic Neoplasms
/
Biological Products
/
Vaccines
/
Combined Modality Therapy
/
Angiogenesis Inhibitors
/
Taxoids
/
Therapeutic Uses
/
Drug Therapy
/
Drug Therapy, Combination
/
Antineoplastic Agents
Type of study:
Practice guideline
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS